Dr. Daniel H. Shevrin, MD
Medical Oncology (Medical Oncology Physician)
2650 Ridge Ave., Kellogg Cancer Center
Evanston, IL 60201
Who else practices at this address →
Cook County includes primary care (3% of residents) and mental health (4% of residents) shortage areas. About shortage areas
- Medicare participating
At a glance
- Medical school
- University of Kansas School of Med (Kc/Wich/Sal) (1977)
- Years since graduation
- 49
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 352
Licensed in Illinois since 1979, according to the Illinois Department of Financial and Professional Regulation. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1977Medical school: University of Kansas School of Med (Kc/Wich/Sal)
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Medical Oncology Physician primary
IL license 036059734 (first issued 1979; active)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Northshore University Healthsystem - Evanston Hospital Evanston, IL
- Swedish Hospital Chicago, IL
Medical groups
- Endeavor Health Medical Group (3,350 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 352
- Services billed
- 1,182
- Patients’ average age
- 78
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 692 | 268 |
| Established patient office or other outpatient visit, 20-29 minutes | 239 | 145 |
| Established patient office or other outpatient visit, 40-54 minutes | 126 | 82 |
| Telephone medical discussion with physician, 11-20 minutes | 59 | 46 |
| Telephone medical discussion with physician, 21-30 minutes | 31 | 23 |
| New patient office or other outpatient visit, 60-74 minutes | 29 | 29 |
| Telephone medical discussion with physician, 5-10 minutes | 28 | 23 |
| New patient office or other outpatient visit, 45-59 minutes | 23 | 23 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 13 | 12 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Abiraterone Acetate | 424 |
| Prednisone Other prescribers in Evanston, IL | 284 |
| Erleada (apalutamide) | 106 |
| Xtandi (enzalutamide) | 98 |
| Dexamethasone Other prescribers in Evanston, IL | 74 |
| Gabapentin Other prescribers in Evanston, IL | 63 |
| Potassium Chloride Other prescribers in Evanston, IL | 51 |
| Bicalutamide | 40 |
| Nubeqa (darolutamide) | 35 |
| Orgovyx (relugolix) | 34 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 1 companies reported 1 payments worth $71.03 in total to this clinician.
| AstraZeneca Pharmaceuticals LP | $71.03 |
|---|
| Food and Beverage | $71.03 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 2 industry-funded studies in 2025, from 2 companies. The companies reported $5,838 in research payments for these studies, mostly to the institutions running them.
- Randomized Study to Evaluate MACE in Patients With Prostate Cancer Treated With Relugolix or Leuprolide Acetate
Sumitomo Pharma America, Inc. · Completed · NCT05605964 - Protocol 212082PCR2005 ?A Multicenter, Open-label, Single-arm, Phase 2 Study of Abiraterone Acetate Plus Prednisone in subjects with Advanced Prostate Cancer Without Radiographic Evidence of Metastatic Disease?
Janssen Research & Development, LLC
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.